CTLA4 dual blocker, in patients with advanced solid tumors

Overview of attention for article published in Journal of Hematology & Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#4 of 1,282)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 48 followers.

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors https://t.co/psvybTI3Hs https://t.co/GscMWOW9Kc

First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors https://t.co/1yq0GSbtIM https://t.co/n8dfQy5fYU

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.